leisure time -WSS

leisure time

author：knowledge 2025-08-19 15:01:49 - browse：77

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Many immigrants are left out of maternal health programs

focus

WSS

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Trump team launching legal defense fund to help pay legal bills

Canadians with cystic fibrosis outlive Americans by a decade

Doctors increasingly discourage vaping amid mounting health concerns

STAT wants to know your pick for a great summer read or listen

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Dexcom's push to bring CGM to type 2 diabetes patients

Sports medicine is finally prioritizing gender equality

Dexcom's push to bring CGM to type 2 diabetes patients

The high cost of giving birth even with insurance

Campaign finance charge dropped from case against Sam Bankman

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

'Weather

In Memoriam: Notable people who died in 2023

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

entertainment

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

House GOP plan to stem drug shortages differs from Democrats’

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

What affirmative action's end means to a medical student

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Snowpack in the West is melting rapidly. Where will all that extra water go?

knowledge

hotspot

focus

entertainment